Organisation paid for research Program year 2025 Source: CMS Open Payments

Advanced Urology

Neither a doctor nor a teaching hospital

Research payments

$1,301,300

70 payments

Through program year 2025, Advanced Urology is reported as receiving $1,301,300 in research payments, across 70 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$57,356	2
2024	Research	$74,812	3
2023	Research	$359,025	3
2022	Research	$346,655	5
2021	Research	$313,795	3
2020	Research	$93,321	47
2019	Research	$56,335	7

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $1,301,300 70 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na to BCG Treatment KEYNOTE-676 $1,019,475 11 payments
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment KEYNOTE-676 $86,693 9 payments
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment KEYNOTE-676 $80,181 4 payments
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i $37,491 1 payment
A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab MK-3475 in Combination with Bacillus Calmette-Guerin BCG in Participants with High Risk Non-muscle Invasive Bladder Cancer NMIBC that is Persistent or Recurrent Following BCG Induction KEYNOTE-676 $27,423 2 payments
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i $19,865 1 payment
A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab MK-3475 in Combination with Bacillus Calmette-Guerin BCG in Participants with High Risk Non-muscle Invasive Bladder Cancer NMIBC that is Persistent or Recurrent Following BCG Induction KEYNOTE-676 $15,000 2 payments
A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab MK-3475 in Combination with Bacillus Calmette-Guerin BCG in Participants with High Risk Non-muscle Invasive Bladder Cancer NMIBC that is Persistent or Recurrent Following BCG Induction KEYNOTE-676 $13,912 3 payments
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment KEYNOTE-676 $1,260 37 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.